98%
921
2 minutes
20
Objectives: Partial volume effects in positron emission tomography occur frequently in neurodegenerative diseases due to increasing cortical atrophy during the disease course, and fronto-temporal dementia is often characterized by severe atrophy. The aim of this study was to challenge partial volume effect correction (PVEC) in patients with nonfluent-agrammatic variant primary progressive aphasia (nfv-PPA) imaged with [F]-THK-5351 PET a marker of reactive neuroinflammatory astrogliosis as well as tau-binding.
Methods: Patients with nfv-PPA (n = 20) were imaged with [F]-THK-5351 PET accompanied by structural magnetic resonance tomography imaging (MRI). Region specific cortical grey matter volumes and standard uptake value ratios (SUVr) of the Hammers atlas were compared with eight healthy control (HC) (n = 8) data before and after performing region-based voxel-wise PVEC. We evaluated regional coefficients of variance (CoV) and the number of regions with significant [F]-THK-5351 PET signal differences between nfv-PPA and controls before and after PVEC. Additionally, a blinded visual read was performed by three nuclear medicine physicians (consensus) before and after PVEC.
Results: Prior to PVEC, [F]-THK-5351 tracer uptake was significantly higher in the bilateral frontal cortex of patients with nfv-PPA when compared to HC (left > right), despite significant grey matter atrophy in the same brain regions in patients with nfv-PPA. SUVr differences between nfv-PPA and HC were further increased by PVEC in frontal brain regions, but group level variance increased in parallel and reduced the number of significant differences between SUVr of nfv-PPA and HC (uncorrected: 10 significant regions, CoV[nfv-PPA]: 20.8 % ± 4.7 %, CoV[HC]: 7.9 % ± 2.4 %/PVEC: 3 significant regions, CoV[nfv-PPA]: 28.4 % ± 8.9 %, CoV[HC]: 9.8 % ± 2.5 %). Sensitivity/specificity of the visual read for detection of nfv-PPA was 0.85/1.00 without PVEC and 0.85/0.75 with PVEC.
Conclusions: [F]-THK-5351 PET facilitates detection of pathological alterations in patients with nfvPPA with severe atrophy. PVEC increases quantitative SUVr differences between patients with nfv-PPA and HC but introduces a parallel increase of variance at the group level. Visual assessment of [F]-THK-5351 images in patients with nfv-PPA is impaired by PVEC due to loss of specificity and does not support the use of PVEC even in patients with severe atrophy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056779 | PMC |
http://dx.doi.org/10.1016/j.nicl.2025.103789 | DOI Listing |
Neuroimage Clin
June 2025
Department of Nuclear Medicine, Ludwig-Maximilian-University Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.
Objectives: Partial volume effects in positron emission tomography occur frequently in neurodegenerative diseases due to increasing cortical atrophy during the disease course, and fronto-temporal dementia is often characterized by severe atrophy. The aim of this study was to challenge partial volume effect correction (PVEC) in patients with nonfluent-agrammatic variant primary progressive aphasia (nfv-PPA) imaged with [F]-THK-5351 PET a marker of reactive neuroinflammatory astrogliosis as well as tau-binding.
Methods: Patients with nfv-PPA (n = 20) were imaged with [F]-THK-5351 PET accompanied by structural magnetic resonance tomography imaging (MRI).
Nihon Yakurigaku Zasshi
November 2022
Department of Pharmacology, Tohoku University Graduate School of Medicine.
Alzheimer's disease (AD) is one of the most common causes of dementia in the world. Neurodegeneration, gliosis, and misfolded proteins such as amyloid plaques and tau tangles are neuropathological hallmarks in AD. In vivo imaging of these neuropathological lesions would be good biomarkers to understand pathophysiology as well as surrogate markers for clinical trials.
View Article and Find Full Text PDFJ Clin Neurol
July 2022
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background And Purpose: Alzheimer's disease (AD) does not always mean amyloid positivity. [F]THK-5351 has been shown to be able to detect reactive astrogliosis as well as tau accompanied by neurodegenerative changes. We evaluated the [F]THK-5351 retention patterns in positron-emission tomography (PET) and the clinical characteristics of patients clinically diagnosed with AD dementia who had negative amyloid PET findings.
View Article and Find Full Text PDFFront Neurosci
February 2022
Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Many neurodegenerative diseases are neuropathologically characterized by neuronal loss, gliosis, and the deposition of misfolded proteins such as β-amyloid (Aβ) plaques and tau tangles in Alzheimer's disease (AD). In postmortem AD brains, reactive astrocytes and activated microglia are observed surrounding Aβ plaques and tau tangles. These activated glial cells secrete pro-inflammatory cytokines and reactive oxygen species, which may contribute to neurodegeneration.
View Article and Find Full Text PDFWorld J Nucl Med
June 2020
National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
Abnormal beta-amyloid plaques and tau protein accumulation are the core pathologic features of Alzheimer's disease. However, the accumulation of these proteins is also common in cognitively normal elderly people. Therefore, this study is aimed to evaluate the amyloid and tau accumulation in the cognitively normal population.
View Article and Find Full Text PDF